NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) has received a notice of allowance from the U.S. Patent and Trademark Office (USPTO) for a key patent that strengthens the company's intellectual property position in neural probe manufacturing. The patent, titled "Methods for Making Probe Devices and Related Devices," covers novel manufacturing methods for neural probe devices and represents a strategic addition to the company's technology platform.
Patent Details and Strategic Importance
The approved patent application (U.S. Patent Application 17/392,773) covers specific manufacturing processes for neural probe devices, including detailed steps for the arrangement of probe components and deposition of electrode contact material. A Notice of Allowance is issued by the USPTO after examination of a patent application and a determination that a patent should be granted. NeuroOne anticipates the patent will be formally issued in the coming months.
"One of the key aspects with this patent relates to the novel method of electrode material deposition for all of our electrodes that are both commercially available and in development," said Dave Rosa, Chief Executive Officer of NeuroOne. "We believe that this new patent will better protect and advance our entire technology platform as we continue to develop and introduce new applications."
Expanding Intellectual Property Portfolio
This patent approval expands NeuroOne's intellectual property portfolio to 17 issued and pending patents in the United States and internationally. The company's patent portfolio covers a wide variety of thin-film electrode technologies, including both neural and spinal cord electrodes with unique structures designed to optimize functionality while minimizing electrode profile.
Technology Applications and Target Conditions
NeuroOne is developing and commercializing minimally invasive and high-definition solutions for EEG recording, monitoring, ablation, drug delivery and stimulation for patients with various neurological disorders. The company's technology platform targets epilepsy, Parkinson's disease, dystonia, essential tremors, and chronic pain due to failed back surgeries, with the goal of improving patient outcomes and reducing procedural costs.
The company may also pursue applications in additional therapeutic areas including depression, mood disorders, pain, incontinence, high blood pressure, and artificial intelligence applications. This broad therapeutic scope demonstrates the versatility of NeuroOne's neural probe technology platform and its potential for addressing multiple unmet medical needs in neurology.
